Oxford Asset Management’s Quest Diagnostics DGX Stock Holding History

Oxford Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,456	Closed	-$253K	–	537
2025 Q4	$253K	Buy	+1,456	New	+$265K	0.09%	333
2020 Q1	–	Sell	-8,991	Closed	-$960K	–	507
2019 Q4	$960K	Sell	8,991 -79,630	-90%	-$8.3M	0.03%	888
2019 Q3	$9.48M	Buy	+88,621	New	+$9.1M	0.23%	100
2019 Q2	–	Sell	-13,919	Closed	-$1.25M	–	1756
2019 Q1	$1.25M	Sell	13,919 -88,626	-86%	-$7.68M	0.03%	819
2018 Q4	$8.54M	Buy	102,545 +40,370	+65%	+$3.78M	0.22%	99
2018 Q3	$6.69M	Buy	62,175 +54,017	+662%	+$5.92M	0.14%	156
2018 Q2	$900K	Sell	8,158 -45,099	-85%	-$4.7M	0.02%	1096
2018 Q1	$5.34M	Sell	53,257 -1,813	-3%	-$186K	0.11%	176
2017 Q4	$5.45M	Sell	55,070 -469	-0.8%	-$44.5K	0.12%	210
2017 Q3	$5.18M	Sell	55,539 -7,315	-12%	-$777K	0.1%	218
2017 Q2	$6.99M	Buy	+62,854	New	+$6.65M	0.14%	150

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Oxford Asset Management's DGX Position: Q1 2026 in Review

Oxford Asset Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,456 shares — an estimated $253K sold.

Oxford Asset Management first reported a position in DGX in Q2 2017 and held it in 11 quarters. The position peaked at $9.48M in Q3 2019. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Oxford Asset Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Oxford Asset Management sold 1,456 Quest Diagnostics shares in Q1 2026, an estimated $253K.
Oxford Asset Management first reported a position in Quest Diagnostics in Q2 2017 and held it in 11 quarters.
Oxford Asset Management's Quest Diagnostics position peaked at $9.48M in Q3 2019.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.